 | How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 25 at 8:01 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 24 at 8:03 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 23 at 8:04 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 22 at 8:06 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 21 at 8:01 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 20 at 8:01 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 19 at 8:04 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 18 at 8:25 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 17 at 5:56 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 17 at 5:55 PM |
|
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 17 at 5:54 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 16 at 5:26 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 15 at 5:15 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 14 at 5:01 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 13 at 5:17 PM |
| How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 12 at 5:11 PM |
| AbbVie (NYSE:ABBV) Upgraded to Sell at BidaskClub
marketbeat.com - January 1 at 3:07 AM |
| Three High-Yield Dividend Stocks For 2021 And Beyond (ABBV)
marketbeat.com - December 29 at 8:39 AM |
| AbbVie (NYSE:ABBV) Downgraded to Strong Sell at BidaskClub
marketbeat.com - December 19 at 12:04 AM |
| AbbVie (NYSE:ABBV) Price Target Raised to $120.00 at Morgan Stanley
marketbeat.com - November 30 at 8:37 AM |
 | Doing underway in Alector, AbbVie's study of AL002 in Alzheimer’s disease - Seeking Alpha
seekingalpha.com - January 25 at 1:25 PM |
 | European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - PRNewswire
prnewswire.com - January 25 at 1:25 PM |
 | European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
finance.yahoo.com - January 25 at 1:24 PM |
 | Breast Cancer Drugs Market : Segments Worth Observing Aiding Growth Factors | Hoffmann-La Roche Ltd., AbbVie Inc
marketwatch.com - January 25 at 3:24 AM |
| AbbVie Is Raising Several Green Flags - Seeking Alpha
seekingalpha.com - January 22 at 12:18 PM |
 | $13.74 Billion in Sales Expected for AbbVie Inc. (NYSE:ABBV) This Quarter
americanbankingnews.com - January 21 at 1:22 PM |
| AbbVie Stock Is Trading Near A 3-Year High — Is It Time To Add ABBV Stock?
finance.yahoo.com - January 19 at 3:57 PM |
| AbbVie: Undervalued Dividend Aristocrat Offering A 4.77% Yield - Seeking Alpha
seekingalpha.com - January 18 at 11:22 AM |
| Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference - Yahoo Finance
finance.yahoo.com - January 16 at 10:21 AM |
| AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of "Buy" from Brokerages
americanbankingnews.com - January 16 at 10:17 AM |
|
| Zacks: Analysts Anticipate AbbVie Inc. (NYSE:ABBV) Will Post Earnings of $2.86 Per Share
americanbankingnews.com - January 16 at 8:34 AM |
| Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference - PRNewswire
prnewswire.com - January 15 at 1:00 PM |
| Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
finance.yahoo.com - January 15 at 1:00 PM |
 | 3 Green Flags for AbbVie in 2021 and 1 Red Flag - Motley Fool
fool.com - January 15 at 7:04 AM |
| Traders Buy High Volume of AbbVie Call Options (NYSE:ABBV)
americanbankingnews.com - January 13 at 8:56 PM |
| Genmab receives $40M milestone payment in AbbVie collaboration - Seeking Alpha
seekingalpha.com - January 13 at 3:53 PM |
 | Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie - GlobeNewswire
globenewswire.com - January 13 at 3:53 PM |
| AbbVie (ABBV) Inks Deal to Acquire Medical Device Company - Yahoo Finance
finance.yahoo.com - January 13 at 3:53 PM |
| AbbVie (ABBV) Inks Deal to Acquire Medical Device Company
finance.yahoo.com - January 13 at 3:53 PM |
| Evolus is up 6% after AbbVie-Cypris Medical deal
seekingalpha.com - January 13 at 11:03 AM |
| AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - January 13 at 7:55 AM |
| AbbVie in-licenses Dragonfly Therapeutics' TriNKET drug candidate - Seeking Alpha
seekingalpha.com - January 12 at 10:29 PM |
| AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call - Yahoo Finance
finance.yahoo.com - January 12 at 10:29 PM |
 | AbbVie (ABBV) to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call - StreetInsider.com
streetinsider.com - January 12 at 11:35 AM |
| Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate - PRNewswire
prnewswire.com - January 12 at 11:35 AM |
| Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
finance.yahoo.com - January 12 at 11:35 AM |
| AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call
finance.yahoo.com - January 12 at 11:35 AM |
| AbbVie rated buy at Mizuho despite patent cliff for Humira - Seeking Alpha
seekingalpha.com - January 11 at 2:07 PM |
| AbbVie (NYSE:ABBV) Reaches New 12-Month High at $109.21
americanbankingnews.com - January 11 at 1:31 PM |
| AbbVie Looks Attractive Despite Headwinds - Seeking Alpha
seekingalpha.com - January 10 at 11:05 PM |
| Dividend Diligence On AbbVie With Seeking Alpha - Seeking Alpha
seekingalpha.com - January 10 at 11:05 PM |
| AbbVie Looks Attractive Despite Headwinds
seekingalpha.com - January 10 at 9:54 PM |
| AbbVie Inc. (NYSE:ABBV) Pays A US$1.30 Dividend In Just Four Days - Yahoo Finance
finance.yahoo.com - January 9 at 6:43 PM |
| How Safe Is AbbVie's Dividend? - Motley Fool
fool.com - January 9 at 1:43 PM |
 | AbbVie Inc. (NYSE:ABBV) Will Pay A US$1.30 Dividend In Four Days
nasdaq.com - January 9 at 8:40 AM |
| How Safe Is AbbVie's Dividend?
finance.yahoo.com - January 9 at 8:40 AM |
| AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies - Yahoo Finance
finance.yahoo.com - January 9 at 3:39 AM |
| AbbVie (ABBV) to Present at the 39th Annual J.P. Morgan Healthcare Conference
marketwatch.com - January 8 at 10:38 PM |
| Victoria Park Medispa Launches Emsculpt NEO in Canada
finance.yahoo.com - January 8 at 10:38 PM |
| AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies - Nasdaq
nasdaq.com - January 8 at 12:34 PM |
 | How Patience Paid Off for Jim Cramer With AbbVie - TheStreet
thestreet.com - January 8 at 12:34 PM |
| AbbVie : Skyrizi Shows Improvements In Clinical Responses In Two Phase 3 Studies On Crohn's Disease - Nasdaq
nasdaq.com - January 7 at 9:32 PM |
| Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease - PRNewswire
prnewswire.com - January 7 at 10:39 AM |
| Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
finance.yahoo.com - January 7 at 10:39 AM |
| Insights on the Botulinum Toxin Global Market to 2024 - Featuring Abbvie, Ipsen and Revance Therapeutics - Yahoo Finance
finance.yahoo.com - January 6 at 2:38 PM |
| AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies - Nasdaq
nasdaq.com - January 6 at 2:38 PM |
| Why AbbVie (ABBV) Could Beat Earnings Estimates Again - Nasdaq
nasdaq.com - January 6 at 2:38 PM |
| AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
finance.yahoo.com - January 6 at 2:38 PM |
| AbbVie's risankizumab shows positive action in patients with psoriatic arthritis - Seeking Alpha
seekingalpha.com - January 5 at 8:19 PM |
| AbbVie (ABBV) Announces Risankizumab Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients - StreetInsider.com
streetinsider.com - January 5 at 3:14 PM |
